Bioidentical Hormone Replacement Therapy: Evidence, Options, and Clinical Judgment

Prepared by Daniel Soule
Director, HormoneSynergy® Clinic LLC
Portland & Lake Oswego, Oregon | USA

Bioidentical hormone replacement therapy has become a confusing subject because almost everyone talking about it is selling something.

Some conventional sources still speak as if all hormone therapy is dangerous because of the Women’s Health Initiative headlines from 2002. Some wellness marketers speak as if hormones are the missing answer to everything: weight, mood, sex drive, skin, brain, sleep, energy, and aging itself.

Both positions are too simple.

Hormones are powerful. Declining hormones can cause real symptoms. Hormone therapy can help many people when it is used carefully. It can also cause harm when it is prescribed casually, dosed aggressively, poorly monitored, or sold as anti-aging magic.

At HormoneSynergy®, we have used bioidentical hormone replacement therapy for more than two decades. Not because it is fashionable. It was not fashionable for most of that time. We use it because, in the right patient, with the right evaluation and the right follow-up, it can be a meaningful part of medical care.

But BHRT is not step one. It is not a substitute for sleep, strength, metabolic health, nutrition, stress physiology, detoxification capacity, cardiovascular risk assessment, or honest clinical judgment.

Hormones can help restore capacity. They cannot replace the foundation.

What “bioidentical” actually means

The word bioidentical refers to molecular structure. A bioidentical hormone has the same chemical structure as a hormone made by the human body.

It does not automatically mean natural. It does not automatically mean safer. It does not automatically mean compounded. It does not automatically mean unregulated. It does not automatically mean better.

That language has been badly distorted.

Estradiol patches, estradiol gels, vaginal estradiol, and oral micronized progesterone can all be FDA-approved and bioidentical. Compounded estradiol, progesterone, testosterone, DHEA, or estriol may also be bioidentical in structure, but compounded medication is a different category from FDA-approved medication.

Premarin®, made from pregnant mare urine, has often been called “natural” because it comes from an animal source. But it is not identical to the primary estrogens made by a human ovary. Provera® is medroxyprogesterone acetate, a synthetic progestin, not progesterone. Methyltestosterone is a synthetic oral androgen with liver-safety concerns and is not the same as physiologic testosterone.

So the first rule is simple: do not confuse natural, bioidentical, FDA-approved, and compounded. They are separate questions.

Hormones are not the foundation

Hormone replacement works best when the rest of the body is not being ignored.

The foundation still matters: sleep, protein, resistance training, glucose control, stress physiology, alcohol use, thyroid status, nutrient status, cardiometabolic risk, gut function, environmental exposures, and body composition.

Hormones sit on top of that foundation. They do not create it.

The HormoneSynergy® framework has always placed hormone therapy after the basics:

1. Decrease stress physiology.
2. Eat a healthy diet and keep blood sugar stable.
3. Exercise, including resistance training.
4. Sleep well and sleep enough.
5. Reduce toxin exposure and support detoxification capacity.
6. Maintain healthy weight, muscle, and visceral fat levels.
7. Use targeted supplements when appropriate.
8. Consider bioidentical hormone replacement therapy after weighing individual risks and benefits.

That order is intentional.

A woman with severe night sweats, insomnia, bone loss, and genitourinary symptoms may benefit greatly from hormone therapy. A man with profound testosterone deficiency may benefit from carefully monitored testosterone replacement. But no one should be told that hormones are the entire plan.

In longevity medicine, the question is not whether a treatment sounds exciting. The question is whether it improves capacity, reduces risk, and can be monitored responsibly.

Why the hormone conversation changed after the Women’s Health Initiative

In 2002, the Women’s Health Initiative changed hormone therapy almost overnight.

The public message became simple: hormone therapy increases breast cancer, heart disease, stroke, blood clots, and dementia. Prescribing dropped. Fear replaced nuance.

The problem is that the study was not a study of all hormone therapy, all women, all ages, all routes, or all hormone formulations.

Much of the fear came from data involving oral conjugated equine estrogen plus medroxyprogesterone acetate in a population that included many women who were older and further from menopause than the typical symptomatic patient seeking care in perimenopause or early menopause.

That does not mean the Women’s Health Initiative should be dismissed. It should not. It taught medicine important lessons about risk, timing, route, formulation, and the danger of assuming hormone therapy prevents chronic disease in everyone.

But it also should not be used as a blunt instrument against every form of hormone therapy.

What current menopause guidance says

The North American Menopause Society’s 2022 position statement describes hormone therapy as the most effective treatment for vasomotor symptoms, including hot flashes and night sweats, and for genitourinary syndrome of menopause. It also recognizes prevention of bone loss and fracture as a known benefit of hormone therapy.

The same statement emphasizes personalization, shared decision-making, route selection, dose selection, duration, and periodic reevaluation. It also recommends risk stratification by age and time since menopause.

For many healthy symptomatic women who are younger than 60 or within 10 years of menopause onset, the benefits of hormone therapy may outweigh the risks. For women who are older, further from menopause, or medically complex, the calculation changes.

Transdermal estrogen and lower doses may reduce the risk of venous thromboembolism and stroke compared with oral estrogen. Vaginal estrogen can often be used for genitourinary symptoms at very low doses with minimal systemic absorption.

That is the modern conversation. Not hormone fear. Not hormone hype. Risk stratification.

The FDA label change: important, but not permission to be careless

In 2026, the FDA approved labeling changes for several menopause hormone therapies, removing certain older warning language around cardiovascular disease, breast cancer, and probable dementia from the labels of selected products.

This was an important correction to decades of oversimplified fear.

It does not mean hormone therapy is risk-free. It does not mean every woman should take hormones. It does not mean older data should be ignored. It does not mean compounded hormones are automatically safer. It does not mean hormone therapy should be used without screening or follow-up.

It means the conversation is finally becoming more specific.

Who may benefit from hormone therapy?

Patients seek hormone therapy for many reasons. Some are clearly menopause-related. Some are partly hormone-related. Some have nothing to do with hormones at all.

Possible hormone-related concerns may include:

• Hot flashes
• Night sweats
• Sleep disruption
• Menstrual irregularity in perimenopause
• Mood changes
• Irritability
• Anxiety or depressive symptoms during the menopausal transition
• Brain fog
• Reduced concentration
• Low libido
• Vaginal dryness
• Painful intercourse
• Recurrent urinary symptoms
• Loss of muscle tone or strength
• Bone loss
• Joint stiffness or pain
• Skin and hair changes
• Fatigue

This list is not a diagnosis. It is a starting point.

Brain fog may be worsened by low estrogen, poor sleep, insulin resistance, thyroid disease, B12 deficiency, depression, medication effects, alcohol, sleep apnea, chronic stress, or early cognitive disease. Fatigue may be hormonal, metabolic, inflammatory, nutritional, cardiovascular, psychological, sleep-related, or medication-related. Low libido may involve hormones, relationship context, pain, pelvic floor dysfunction, antidepressants, trauma history, body image, sleep, or chronic stress.

Hormones may be part of the answer. They should not be assumed to be the whole answer.

Estrogen: route matters

Estrogen is not one thing.

There are different estrogens, different routes, different doses, and different risk profiles. Oral estradiol, transdermal estradiol, vaginal estradiol, estriol, conjugated equine estrogen, pellets, gels, patches, creams, sprays, rings, and tablets should not be discussed as if they are interchangeable.

Oral estrogen passes through the liver first. This first-pass hepatic effect can influence clotting factors, triglycerides, inflammatory markers, binding proteins, and estrogen metabolite patterns. Oral estrogen can be effective for symptoms, but it is not usually our first choice when safer or more physiologic routes are appropriate.

Transdermal estradiol, including patches and gels, bypasses first-pass liver metabolism and provides more stable systemic delivery for many patients. For women with clotting risk concerns, migraine history, metabolic risk, elevated triglycerides, or cardiovascular risk factors, route matters.

Vaginal estrogen is different again. Low-dose vaginal estradiol or estriol may be used for genitourinary syndrome of menopause, including vaginal dryness, pain with intercourse, urinary urgency, and recurrent urinary symptoms. In many cases, systemic exposure is low. For some women, vaginal estrogen is the most useful and least complicated hormone intervention.

Progesterone is not Provera®

Progesterone and synthetic progestins are often placed in the same mental bucket. They do not belong there.

Progesterone is the hormone made by the human body. Micronized progesterone is bioidentical. Provera® is medroxyprogesterone acetate, a synthetic progestin. Synthetic progestins can have different effects on breast tissue, vascular biology, mood, fluid retention, and metabolic markers than micronized progesterone.

For women with a uterus, progesterone is usually required when systemic estrogen is prescribed. Estrogen can stimulate the uterine lining. Progesterone helps protect against endometrial overgrowth and endometrial cancer.

There are exceptions with very low-dose local vaginal estrogen used only for genitourinary symptoms, but systemic estrogen in a woman with a uterus requires a uterine-protection plan.

Oral micronized progesterone may also help sleep in some women because of its neuroactive metabolites. This does not mean everyone tolerates it well. Some patients feel groggy, depressed, bloated, or emotionally flat. Some do better with cyclic dosing. Some do better with different timing. Some need a different approach.

Progesterone is not a throwaway add-on. It is part of the treatment design.

Testosterone in women: useful, overmarketed, and often mishandled

Women make testosterone. Women need androgens. That part is not controversial.

The problem is how testosterone is often marketed.

Low libido, low motivation, low energy, poor recovery, reduced muscle, and low mood are not automatically testosterone deficiencies. They may involve sleep, stress, relationship strain, pain, antidepressants, thyroid dysfunction, iron deficiency, insulin resistance, under-eating, overtraining, trauma, menopause, or a mix of factors.

Testosterone can be beneficial for many women, not just for sexual desire but also for maintaining muscle mass, cognitive sharpness, energy, and recovery. While it’s normal for levels to decline with age, optimizing testosterone to support well-being can be valuable. The key is individualized dosing, women don’t need male levels, but they do benefit from achieving an optimal range based on both symptoms and labs.

Of course, careful monitoring is crucial. Potential side effects—though not common at appropriate doses—can include acne, oily skin, unwanted hair growth, or voice changes. That’s why we aim for physiological ranges that enhance vitality without pushing extremes.

Testosterone in men: replacement is not the same as enhancement

Men also need careful evaluation before testosterone therapy.

A low testosterone number is not enough. We look at symptoms, repeat morning levels, free testosterone, SHBG, estradiol, LH/FSH when appropriate, prolactin when indicated, thyroid status, sleep apnea risk, body composition, alcohol use, insulin resistance, medications, fertility goals, prostate health, hematocrit, cardiovascular risk, and the bigger clinical picture.

Testosterone therapy can benefit men with confirmed low testosterone, often improving libido, energy, mood, bone density, and muscle mass. It’s about restoring balance and well-being when levels are truly suboptimal.

As with any therapy, care is needed. If not properly managed, side effects like acne, elevated red blood cells, fertility suppression, or sleep apnea complications can arise. Thoughtful dosing, regular follow-up, and personalized goals help maximize benefits and minimize risks.

Men do not need testosterone clinics. They need medical evaluation.

Pellets: convenient, but not automatically better

Hormone pellets are often marketed as the cleanest, most natural, most convenient form of hormone replacement. The appeal is obvious: a small implant, steady delivery, fewer daily decisions.

Pellets can work well for some patients.

Pellets can be convenient, but they come with challenges. Once placed, the dose can’t be easily adjusted. If it’s too high, you might experience lingering effects—like bleeding, breast tenderness, or hormonal shifts—for months. That’s why careful, experienced oversight is key. A knowledgeable physician with years of hormone therapy experience should guide this—not a marketing-first approach. The goal isn’t chasing numbers; it’s safe, effective symptom relief.

Compounded hormones: sometimes useful, never casual

Compounded hormones can be clinically useful when a patient needs a dose, route, combination, or excipient profile not available in an FDA-approved product.

But compounded hormones should not be marketed as safer, cleaner, more natural, or more effective simply because they are compounded.

Compounding adds variables: pharmacy quality, potency, sterility when relevant, ingredient sourcing, formulation consistency, absorption, labeling, oversight, and patient instructions. Not all compounding pharmacies are equal.

At HormoneSynergy®, when compounded medications are used, we use reputable compounding pharmacies with appropriate quality standards. We do not use gray-market hormones. We do not use casual online sources. We do not treat compounding as a loophole around medical standards.

FDA-approved options are often preferred when they fit the patient’s needs. Compounded options are reserved for situations where individualization is clinically useful.

Hormone testing: useful, but not magic

Testing can help. It can also mislead.

Baseline testing may help clarify menopausal status, ovarian reserve, androgen status, thyroid function, adrenal patterns, insulin resistance, nutrient deficiencies, inflammation, liver function, kidney function, lipid risk, bone risk, and metabolic context.

Follow-up testing can help determine whether a patient is receiving too much hormone, whether levels are in a reasonable range, and whether side effects or symptoms match the biology.

But hormone testing does not replace clinical judgment. Saliva, serum, urine, and dried urine testing each have strengths and limitations. A lab value should never be treated as the patient.

Symptoms matter. Safety markers matter. Risk factors matter. Dose matters. Route matters. Timing matters. The patient sitting in front of us matters most.

Breast cancer risk: the question patients are right to ask

Many patients want to know whether hormone therapy increases breast cancer risk.

The honest answer is: it depends.

Risk depends on personal history, family history, genetics, breast density, alcohol use, body composition, insulin resistance, prior biopsies, age, time since menopause, estrogen exposure, progesterone or progestin choice, duration of therapy, and whether the uterus is present.

Estrogen-only therapy and estrogen-plus-progestogen therapy do not have identical risk profiles. Micronized progesterone and synthetic progestins may not behave the same way. Short-term and long-term use are different conversations. A woman with no uterus is not in the same category as a woman who needs endometrial protection. A patient with a personal history of hormone-sensitive breast cancer requires a different level of caution.

This is why screening and context matter. Mammography, breast density, risk models, family history, prior imaging, genetic risk when appropriate, and shared decision-making all belong in the conversation.

Fear is not informed consent. Neither is reassurance without evaluation.

Cardiovascular risk: estrogen is not a statin, but route and timing matter

Hormone therapy should not be prescribed as a blanket strategy to prevent heart disease.

Cardiovascular risk needs its own workup: blood pressure, apoB, LDL particle burden when appropriate, Lp(a), triglycerides, insulin resistance, inflammatory markers, visceral fat, smoking history, family history, sleep apnea risk, fitness, body composition, and imaging when indicated.

Estrogen may influence vascular function, lipids, insulin sensitivity, inflammation, and body composition. But the clinical effect depends on timing, route, dose, baseline vascular health, and patient selection.

Starting hormone therapy in a healthy symptomatic woman near menopause is not the same as starting systemic estrogen in an older woman decades after menopause with established plaque burden.

That is why we integrate hormone decisions with preventive cardiology rather than pretending they are separate.

Bone health: one of the clearest benefits

Estrogen helps preserve bone. Loss of estrogen after menopause accelerates bone resorption and increases risk for osteopenia, osteoporosis, and fracture.

Hormone therapy can help prevent bone loss and reduce fracture risk in appropriately selected women. But bone health is not just estrogen.

We also evaluate DEXA results, trabecular bone score when available, visceral fat, muscle mass, protein intake, vitamin D status, calcium intake, magnesium, vitamin K2 when appropriate, resistance training, balance, fall risk, thyroid status, parathyroid status, inflammatory disease, medications, alcohol, and gastrointestinal absorption.

A woman with osteoporosis deserves more than “take hormones” or “take a bisphosphonate.” She deserves a full fracture-risk strategy.

Brain, mood, and sleep: real effects, careful claims

Many women describe brain fog, word-finding problems, sleep disruption, mood volatility, anxiety, or depressive symptoms during perimenopause and menopause.

These symptoms are real. They are not character flaws. They are not just stress. Hormonal fluctuation can affect neurotransmitters, thermoregulation, sleep architecture, insulin sensitivity, inflammation, and vascular function.

Estrogen therapy may improve sleep indirectly by reducing hot flashes and night sweats. In some women, it may also improve mood or cognition-related symptoms during the menopausal transition. Progesterone may help sleep in some patients. Testosterone may improve sexual desire or motivation in selected patients.

But hormone therapy should not be sold as dementia prevention. Cognitive health requires a broader approach: sleep, exercise, insulin sensitivity, blood pressure, apoB, hearing, mood, alcohol, sleep apnea, strength, social connection, inflammation, nutrient status, and vascular risk.

Brain fog deserves evaluation, not a hormone sales pitch.

Genitourinary syndrome of menopause: often undertreated

Vaginal dryness, painful intercourse, urinary urgency, recurrent urinary symptoms, and tissue fragility are common after estrogen decline. Many patients are embarrassed to bring this up. Many clinicians do not ask.

Low-dose vaginal estrogen can be one of the most effective and underused tools in menopause care.

It may improve vaginal tissue, comfort with intercourse, urinary symptoms, and quality of life. Because systemic absorption is generally low with many local preparations, it can be considered separately from systemic hormone therapy in many patients.

For some women, this is the only hormone treatment needed.

Who should be more cautious?

Hormone therapy may not be appropriate, or may require specialist-level caution, in patients with certain histories or risks.

These may include:

• Personal history of hormone-sensitive breast cancer
• Unexplained postmenopausal bleeding
• Known or suspected estrogen-dependent cancer
• Active or recent blood clot
• Known thrombophilia
• Prior stroke or certain high-risk cardiovascular histories
• Active liver disease
• Untreated endometrial hyperplasia
• Pregnancy
• Poorly controlled hypertension
• Complex migraine or neurologic history requiring additional review
• Untreated sleep apnea when considering testosterone
• Desire for fertility when considering testosterone in men

This does not mean every item is an absolute contraindication in every case. It means the decision requires medical judgment, documentation, and sometimes coordination with oncology, gynecology, cardiology, hematology, or primary care.

Postmenopausal bleeding is never something to ignore

Any bleeding after menopause requires evaluation.

This is true whether a woman is using hormone therapy or not.

Bleeding can occur from benign causes, including hormone dosing, endometrial thinning, polyps, fibroids, infection, or local tissue changes. But it can also be a sign of endometrial hyperplasia or uterine cancer.

If bleeding occurs after menopause, the answer is not to guess. The answer is evaluation.

The HormoneSynergy® approach

We do not believe in hormone fear.

We also do not believe in hormone worship.

Our approach is evidence-informed, individualized, and cautious where caution is earned.

We ask:

• What symptoms are present?
• When did they start?
• Is the patient perimenopausal, menopausal, postmenopausal, surgically menopausal, or prematurely menopausal?
• What is the patient’s breast, uterine, cardiovascular, clotting, metabolic, bone, and cognitive risk?
• What medications are being used?
• What labs and imaging are needed?
• What is the safest effective route?
• Is an FDA-approved product appropriate?
• Is compounding actually necessary?
• How will we monitor benefit and safety?
• What are we not going to promise?

That last question matters.

We do not promise that hormones will reverse aging. We do not promise that hormones prevent dementia. We do not promise that hormones prevent heart disease. We do not promise that every patient will feel dramatically better.

We do promise to take the question seriously.

What monitoring may include

Monitoring depends on the patient and treatment plan. It may include:

• Symptom review
• Blood pressure
• Weight, waist, muscle, and visceral fat tracking
• Hormone levels when appropriate
• Complete blood count
• Liver and kidney function
• Lipids, apoB, triglycerides, and cardiometabolic markers
• Glucose, insulin, A1c, or CGM data when appropriate
• Thyroid evaluation
• Breast screening coordination
• Pelvic ultrasound or gynecology referral if bleeding occurs
• DEXA monitoring for bone density
• Sleep apnea assessment when indicated
• Prostate and hematocrit monitoring in men using testosterone

Hormone therapy should create a follow-up relationship, not a transaction.

Common myths about BHRT

Myth: Bioidentical hormones are always safe.

No. Bioidentical hormones are still hormones. Dose, route, duration, patient risk, and monitoring matter.

Myth: Compounded hormones are always better.

No. Compounded hormones may be useful when clinically necessary, but FDA-approved options are often preferred when they fit the patient.

Myth: Oral estrogen and transdermal estrogen carry the same risk.

No. Route matters. Oral estrogen has more first-pass liver effect. Transdermal estrogen may reduce certain clotting and stroke risks compared with oral therapy in appropriate patients.

Myth: Progesterone and synthetic progestins are the same.

No. Micronized progesterone and synthetic progestins can have different biologic effects and should not be treated as identical.

Myth: Everyone should stop hormone therapy at 60 or 65.

No. Some patients may appropriately continue therapy beyond those ages after evaluation and counseling. The question is whether the benefit-risk profile still makes sense.

Myth: Hormone therapy is only for hot flashes.

No. Hot flashes and night sweats are common reasons to treat, but bone health, genitourinary symptoms, sleep, mood, and quality of life may also be part of the conversation.

Myth: Hormone therapy is anti-aging medicine.

Not the way the term is usually marketed. Hormone therapy may help restore physiologic function in selected patients. It is not a substitute for the fundamentals of healthspan.

The bottom line

Bioidentical hormone replacement therapy is not fringe medicine. It is also not a wellness toy.

Estradiol, progesterone, and testosterone are real hormones with real effects. They can improve symptoms, quality of life, sexual health, sleep, bone health, and genitourinary function in appropriately selected patients.

They can also create risk when used poorly.

The better question is not whether hormones are good or bad. The better question is whether hormone therapy is appropriate for this patient, at this time, using this route, this dose, this formulation, and this monitoring plan.

That is medicine.

Not marketing.

Related HormoneSynergy® Resources

For more HormoneSynergy® articles and clinical resources, visit the Longevity Medicine Resource Library.

Selected References

• The North American Menopause Society Releases Its 2022 Hormone Therapy Position Statement
• The 2022 Hormone Therapy Position Statement of The North American Menopause Society
• ACOG Clinical Consensus: Compounded Bioidentical Menopausal Hormone Therapy
• Reuters: FDA Approves Labeling Changes to Menopause Hormone Therapies
• Women’s Health Initiative Hormone Therapy Trials: Update and Overview
• ESTHER Study: Route of Estrogen Administration and Venous Thromboembolism Risk
• Kuhl H. Pharmacology of Estrogens and Progestogens: Influence of Different Routes of Administration
• Soares et al. Estradiol for Depressive Disorders in Perimenopausal Women
• Raz and Stamm. Intravaginal Estriol and Recurrent Urinary Tract Infection in Postmenopausal Women
• Cowan et al. Breast Cancer Incidence in Women with Progesterone Deficiency

Editorial Transparency

This article was prepared by HormoneSynergy® Clinic for patient education. It reflects clinical experience, current menopause hormone therapy guidance, older HormoneSynergy® educational materials, and updated medical literature. It is not a substitute for individualized medical care. Hormone therapy decisions should be made with a qualified clinician who can review symptoms, personal history, family history, medications, labs, imaging, and risk factors.